2014 Press Releases

Keyword Search
2014 | 2013 | 2012 | 2011 | 2010
04/10/14AVEO and Biodesix Partner to Co-Develop and Commercialize Ficlatuzumab with a Companion Diagnostic for Treatment of NSCLC
Biodesix to Fund Proof of Concept Study CAMBRIDGE, Mass. & BOULDER, Colo.--(BUSINESS WIRE)--Apr. 10, 2014-- AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ficlatuzumab, with a Biodesix® companion diagnostic test. This agreement and the clinical development program will leverage VeriStrat®... 
Printer Friendly Version
03/20/14AVEO Regains Worldwide Rights to AV-203
Agreement with Biogen Idec allows AVEO to seek partner to accelerate clinical development CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 20, 2014-- AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec. “We are pleased to regain rights for AV-203 as we believe in the potential of this innovative therapy and are looking forward... 
Printer Friendly Version
03/13/14AVEO Oncology Reports Full Year 2013 Financial Results and Outlines 2014 Strategic Plan
- Company ends 2013 with $118M in cash1 - - Focuses internal R&D investment on AV-380 in cachexia - - Intends to advance clinical-stage assets through strategic partnering – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 13, 2014-- AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance. “With the cost-containment measures implemented in th... 
Printer Friendly Version
03/04/14AVEO Announces Timing for Conference Call to Discuss Year-End 2013 Financial Results and Provide Strategic Update for 2014
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 4, 2014-- AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014. AVEO will host a conference call to discuss the company’s financial results as well as provide an update on strategy for 2014 on Thursday, March 13 at 4:30 p.m. (ET). The call can be accessed by dialing 1... 
Printer Friendly Version
02/14/14AVEO and Astellas to End Worldwide Collaboration & License Agreement for Development and Commercialization of Tivozanib
Phase 2 Colorectal Cancer Study Discontinued AVEO to Outline Corporate Strategy During 2013 Financial Results Conference Call on March 13, 2014 CAMBRIDGE, Mass. & TOKYO--(BUSINESS WIRE)--Feb. 14, 2014-- AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational agent tivozani... 
Printer Friendly Version
01/30/14AVEO and Astellas Discontinue Phase 2 Trial of Tivozanib in Breast Cancer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 30, 2014-- AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc. have jointly decided to discontinue the BATON (Biomarker Assessment of Tivozanib in ONcology) breast cancer clinical trial, a Phase 2 study in patients with locally recurrent or metastatic triple negative breast cancer (TNBC), due to insufficient enrollment. AVEO previously announced that enrollment in this study had b... 
Printer Friendly Version